Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807200 | 0.90 | TLR2 (0.62) | MAPK1TLR2ERN1TLR1TLR6 | |
| SCHEMBL6553840 | 0.85 | ALDH1A1 (0.58) | MAPK1TLR2ERN1TLR1TLR6 | |
| SCHEMBL20764578 | 0.85 | TLR2 (0.45) | MAPK1TLR2ERN1TLR1TLR6 | |
| SCHEMBL870959 | 0.85 | ALDH1A1 (0.55) | MAPK1TLR2ERN1TLR1TLR6 | |
| SCHEMBL28504593 | 0.84 | ALDH1A1 (0.53) | MAPK1TLR2ERN1TLR1TLR6 | |
| SCHEMBL8830664 | 0.84 | MAPK1 (0.56) | MAPK1FNTAFNTBPTPN1ALDH1A1 | |
| SCHEMBL2918517 | 0.84 | MAPK1 (0.56) | MAPK1FNTAFNTBPTPN1ALDH1A1 | |
| SCHEMBL3864807 | 0.84 | ERN1 (0.68) | MAPK1TLR2ERN1TLR1TLR6 | |
| Benzene SCHEMBL3155472 | 0.83 | ALDH1A1 (0.58) | MAPK1TLR2ERN1TLR1TLR6 | |
| SCHEMBL18196707 | 0.83 | MAPK1 (0.44) | MAPK1TLR2ERN1TLR1TLR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060362-B2 | Inhibitors of glucose transporters (GLUTs) | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| EP-3814359-B1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTS) | LEAD DISCOVERY CENTER GMBH (DE) | 2022-08-17 | — | — | EP | disclosed |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-07-01 | — | — | US | disclosed |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-07-01 | — | — | US | disclosed |
| EP-3814359-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTS) | Lead Discovery Center GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| US-20190352691-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-11-21 | — | — | US | disclosed |
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20160319322-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-11-03 | — | — | US | disclosed |
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | MERCK & CO., INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1740537-A2 | A PROCESS FOR THE PREPARATION OF 2,2-DISUBSTITUTED PYRROLES | Merck & Co., Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005102996-A2 | A PROCESS FOR THE PREPARATION OF 2,2-DISUBSTITUTED PYRROLES | MERCK & CO., INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| CN-1210166-C | Thermal transfer recording system having amorphous dye phase | POLAROID CORP (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-0975597-A1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998045269-A1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1998-10-15 | — | — | WO | disclosed |
| EP-0357089-B1 | Novel cephem compound as an antimicrobial agent and its preparation | MEJI SEIKA K K (JP) | 1996-03-06 | — | — | EP | disclosed |
| US-5061702-A | CEPHEM COMPOUND AS AN ANTIMICROBIAL AGENT | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1991-10-29 | — | — | US | disclosed |
| EP-0357089-A2 | Novel cephem compound as an antimicrobial agent and its preparation | MEJI SEIKA K.K. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060362-B2 | Inhibitors of glucose transporters (GLUTs) | SLC2A1, SLC2A3, SLC2A4 | MAPK1 657/4885TLR2 603/4885ERN1 4420/4885 |
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | KIF5B, KIF5A, KIF5C | MAPK1 1221/4885TLR2 4865/4885ERN1 3136/4885 |
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | HAMP, SLC40A1, FTH1 | MAPK1 4512/4885TLR2 1387/4885ERN1 3729/4885 |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | SLC2A1, SLC2A3, SLC2A4 | MAPK1 734/4885TLR2 517/4885ERN1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.